Shionogi & Co., Ltd. and Hitachi, Ltd. have launched a solution utilizing generative AI to support the creation of regulatory documents for drug development. This new system aims to significantly streamline the drug development process by reducing the time required for document preparation by up to 50%, thereby accelerating the path to market for new medicines.
This AI-driven solution has the potential to significantly reduce the time and cost associated with regulatory submissions in the pharmaceutical industry. By accelerating document preparation, Shionogi and Hitachi can speed up drug development timelines, leading to faster market entry for new therapies and a competitive advantage in the pharmaceutical R&D landscape.
Shionogi and Hitachi partnered to launch an AI solution for drug development documents.
The solution uses generative AI to reduce document creation time by up to 50%.
This aims to accelerate the drug development and regulatory approval process.
This collaboration between Shionogi and Hitachi is a significant development within Japan's technology and pharmaceutical sectors, showcasing advancements in AI application for drug development and regulatory processes in the region.
The solution uses generative AI to reduce document creation time by up to 50%.
This aims to accelerate the drug development and regulatory approval process.
Sign in to save notes on signals.
Sign In